An increased risk of cardiovascular (CV) diseases has been observed in patients with inflammatory bowel diseases (IBD). The impact of IBD drugs, such as anti-TNF, anti-integrins or anti-JAK, on the risk of CV events in IBD is remains unknown. Aortic pulse wave velocity (aPWV), a measure of aortic stiffness, and carotid intima media thickness (CIMT) are both predictors of cardiovascular events and are increased in patients with IBD. The investigators aimed to prospectively compare the CV risk, CIMT, arterial stiffness and biomarkers of endothelial dysfunction at baseline and after 3 and 12 months of anti-TNF, vedolizumab and tofacitinib.

Inclusion Criteria:

• Ulcerative colitis evolving for at least 6 months,
• Patient older than 18 years,
• Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib,
• Written informed consent.

Exclusion Criteria:

• Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period,
• Patients with a cardiovascular event such as myocardial infarction and stroke,
• Diabetic patient,
• Pregnant women,
• Minor
• people unable to give their consent to participate